HRP20110333T1 - 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci - Google Patents
4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci Download PDFInfo
- Publication number
- HRP20110333T1 HRP20110333T1 HR20110333T HRP20110333T HRP20110333T1 HR P20110333 T1 HRP20110333 T1 HR P20110333T1 HR 20110333 T HR20110333 T HR 20110333T HR P20110333 T HRP20110333 T HR P20110333T HR P20110333 T1 HRP20110333 T1 HR P20110333T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- solvate
- fluorophenoxy
- phenylmethyl
- mixtures
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims 2
- 238000000034 method Methods 0.000 title claims 2
- 238000003786 synthesis reaction Methods 0.000 title claims 2
- ZEFXAHXKTLEBQA-UHFFFAOYSA-N 4-[(3-fluorophenoxy)-phenylmethyl]piperidine;methanesulfonic acid Chemical compound CS(O)(=O)=O.FC1=CC=CC(OC(C2CCNCC2)C=2C=CC=CC=2)=C1 ZEFXAHXKTLEBQA-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract 14
- 239000012453 solvate Substances 0.000 claims abstract 12
- 239000000203 mixture Substances 0.000 claims abstract 11
- 229940098779 methanesulfonic acid Drugs 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 5
- FDHPZDXAAGIHFC-UHFFFAOYSA-N 4-[(3-fluorophenoxy)-phenylmethyl]piperidine Chemical class FC1=CC=CC(OC(C2CCNCC2)C=2C=CC=CC=2)=C1 FDHPZDXAAGIHFC-UHFFFAOYSA-N 0.000 claims abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 13
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- FDHPZDXAAGIHFC-GOSISDBHSA-N 4-[(s)-(3-fluorophenoxy)-phenylmethyl]piperidine Chemical compound FC1=CC=CC(O[C@@H](C2CCNCC2)C=2C=CC=CC=2)=C1 FDHPZDXAAGIHFC-GOSISDBHSA-N 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- -1 3-fluorophenoxy Chemical group 0.000 claims 1
- FDHPZDXAAGIHFC-SFHVURJKSA-N 4-[(r)-(3-fluorophenoxy)-phenylmethyl]piperidine Chemical compound FC1=CC=CC(O[C@H](C2CCNCC2)C=2C=CC=CC=2)=C1 FDHPZDXAAGIHFC-SFHVURJKSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06380112A EP1854785A1 (en) | 2006-05-12 | 2006-05-12 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| US11/486,350 US20070265306A1 (en) | 2006-05-12 | 2006-07-13 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| PCT/EP2007/053582 WO2007131846A1 (en) | 2006-05-12 | 2007-04-12 | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110333T1 true HRP20110333T1 (hr) | 2011-06-30 |
Family
ID=37061190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110333T HRP20110333T1 (hr) | 2006-05-12 | 2011-05-06 | 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20070265306A1 (sl) |
| EP (2) | EP1854785A1 (sl) |
| JP (1) | JP2009536962A (sl) |
| KR (1) | KR20090009971A (sl) |
| CN (1) | CN101443312B (sl) |
| AT (1) | ATE501121T1 (sl) |
| AU (1) | AU2007251663B2 (sl) |
| BR (1) | BRPI0710856A2 (sl) |
| CA (1) | CA2651933A1 (sl) |
| CY (1) | CY1111460T1 (sl) |
| DE (1) | DE602007013040D1 (sl) |
| DK (1) | DK2032534T3 (sl) |
| ES (1) | ES2362683T3 (sl) |
| HK (1) | HK1130053A1 (sl) |
| HR (1) | HRP20110333T1 (sl) |
| MX (1) | MX2008014439A (sl) |
| MY (1) | MY148406A (sl) |
| NO (1) | NO20085052L (sl) |
| NZ (1) | NZ572714A (sl) |
| PL (1) | PL2032534T3 (sl) |
| RS (1) | RS51858B (sl) |
| RU (1) | RU2412169C2 (sl) |
| SI (1) | SI2032534T1 (sl) |
| WO (1) | WO2007131846A1 (sl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| US7888386B2 (en) | 2008-07-24 | 2011-02-15 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
| JP2012524098A (ja) * | 2009-04-15 | 2012-10-11 | セラヴァンス， インコーポレーテッド | ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物 |
| SG177647A1 (en) * | 2009-07-13 | 2012-02-28 | Theravance Inc | 3-phenoxymethylpyrrolidine compounds |
| ES2495366T3 (es) | 2009-07-21 | 2014-09-17 | Theravance, Inc. | Compuestos de 3-fenoximetilpirrolidina |
| CA2811641A1 (en) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Serotonin reuptake inhibitors |
| US8501964B2 (en) | 2010-12-03 | 2013-08-06 | Theravance, Inc. | Serotonin reuptake inhibitors |
| US9002322B2 (en) * | 2011-09-29 | 2015-04-07 | Apple Inc. | Authentication with secondary approver |
| CN104887675B (zh) * | 2014-03-05 | 2018-08-07 | 江苏恩华药业股份有限公司 | [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1203149A (en) * | 1968-06-10 | 1970-08-26 | Ici Ltd | Piperidine derivatives |
| US6518284B2 (en) * | 1998-11-18 | 2003-02-11 | Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. | 4-substituted piperidines |
| ES2157148B1 (es) * | 1998-11-18 | 2002-03-01 | Faes Fabrica Espanola De Produ | Nuevas piperidinas 4-sustituidas. |
| KR100943555B1 (ko) * | 2004-04-30 | 2010-02-22 | 워너-램버트 캄파니 엘엘씨 | 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물 |
| EP1854785A1 (en) * | 2006-05-12 | 2007-11-14 | Faes Farma, S.A. | 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
-
2006
- 2006-05-12 EP EP06380112A patent/EP1854785A1/en not_active Withdrawn
- 2006-07-13 US US11/486,350 patent/US20070265306A1/en not_active Abandoned
-
2007
- 2007-04-12 CA CA002651933A patent/CA2651933A1/en not_active Abandoned
- 2007-04-12 WO PCT/EP2007/053582 patent/WO2007131846A1/en active Application Filing
- 2007-04-12 MY MYPI20084507A patent/MY148406A/en unknown
- 2007-04-12 KR KR1020087030170A patent/KR20090009971A/ko not_active Application Discontinuation
- 2007-04-12 RS RS20110154A patent/RS51858B/en unknown
- 2007-04-12 NZ NZ572714A patent/NZ572714A/en not_active IP Right Cessation
- 2007-04-12 US US12/299,907 patent/US20100004283A1/en not_active Abandoned
- 2007-04-12 ES ES07728049T patent/ES2362683T3/es active Active
- 2007-04-12 SI SI200730543T patent/SI2032534T1/sl unknown
- 2007-04-12 BR BRPI0710856-7A patent/BRPI0710856A2/pt not_active IP Right Cessation
- 2007-04-12 PL PL07728049T patent/PL2032534T3/pl unknown
- 2007-04-12 AT AT07728049T patent/ATE501121T1/de active
- 2007-04-12 CN CN2007800172665A patent/CN101443312B/zh not_active Expired - Fee Related
- 2007-04-12 EP EP07728049A patent/EP2032534B1/en active Active
- 2007-04-12 DK DK07728049.3T patent/DK2032534T3/da active
- 2007-04-12 RU RU2008148941/04A patent/RU2412169C2/ru not_active IP Right Cessation
- 2007-04-12 AU AU2007251663A patent/AU2007251663B2/en not_active Ceased
- 2007-04-12 MX MX2008014439A patent/MX2008014439A/es active IP Right Grant
- 2007-04-12 JP JP2009510383A patent/JP2009536962A/ja not_active Ceased
- 2007-04-12 DE DE602007013040T patent/DE602007013040D1/de active Active
-
2008
- 2008-12-04 NO NO20085052A patent/NO20085052L/no not_active Application Discontinuation
-
2009
- 2009-09-03 HK HK09108045.9A patent/HK1130053A1/xx not_active IP Right Cessation
-
2011
- 2011-05-06 HR HR20110333T patent/HRP20110333T1/hr unknown
- 2011-05-17 CY CY20111100477T patent/CY1111460T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007131846A1 (en) | 2007-11-22 |
| BRPI0710856A2 (pt) | 2011-05-17 |
| CN101443312A (zh) | 2009-05-27 |
| HK1130053A1 (en) | 2009-12-18 |
| NZ572714A (en) | 2010-08-27 |
| CA2651933A1 (en) | 2007-11-22 |
| KR20090009971A (ko) | 2009-01-23 |
| EP2032534A1 (en) | 2009-03-11 |
| AU2007251663B2 (en) | 2012-04-05 |
| ES2362683T3 (es) | 2011-07-11 |
| DE602007013040D1 (de) | 2011-04-21 |
| RU2412169C2 (ru) | 2011-02-20 |
| EP1854785A1 (en) | 2007-11-14 |
| NO20085052L (no) | 2008-12-04 |
| US20070265306A1 (en) | 2007-11-15 |
| SI2032534T1 (sl) | 2011-06-30 |
| JP2009536962A (ja) | 2009-10-22 |
| CN101443312B (zh) | 2011-07-06 |
| RS51858B (en) | 2012-02-29 |
| US20100004283A1 (en) | 2010-01-07 |
| CY1111460T1 (el) | 2015-08-05 |
| EP2032534B1 (en) | 2011-03-09 |
| MX2008014439A (es) | 2009-01-21 |
| DK2032534T3 (da) | 2011-04-26 |
| MY148406A (en) | 2013-04-30 |
| AU2007251663A1 (en) | 2007-11-22 |
| RU2008148941A (ru) | 2010-06-20 |
| PL2032534T3 (pl) | 2011-08-31 |
| ATE501121T1 (de) | 2011-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110333T1 (hr) | 4[(3-fluorfenoksi)fenilmetil]piperidin-metansulfonat: upotreba, postupci sinteze i farmaceutski pripravci | |
| TW200522944A (en) | CB1 modulator compounds | |
| MX2016017332A (es) | Analogos de pridopidina, su preparacion y uso. | |
| AU2002237654B2 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | |
| SG10201407409WA (en) | Inhibitors of jun n-terminal kinase | |
| WO2010018113A3 (en) | Bi-aryl aminotetralines | |
| MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
| TW200619220A (en) | New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | |
| JO2676B1 (en) | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines | |
| TW200602339A (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| JO2769B1 (en) | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor | |
| NO331174B1 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister | |
| PL203071B1 (pl) | Pochodne piperydyny, ich zastosowania, zawierająca je kompozycja farmaceutyczna oraz sposób ich wytwarzania | |
| WO2010018112A3 (en) | Monoaryl aminotetralines | |
| JO2849B1 (en) | Dopamine 2 receptor antagonists are rapidly hydrolyzed | |
| MX2009005507A (es) | Derivados de espiro-piperidina. | |
| EA200701879A1 (ru) | Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина | |
| MX2009011415A (es) | Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion. | |
| EA200600061A1 (ru) | Бензамиды 4-(аминометил) пиперидина как 5нт-антагонисты | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| MY148772A (en) | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| PE20090141A1 (es) | Compuestos derivados de isoquinolina proceso de preparacion y composicion farmaceutica |